Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy Authors: Pan Li, Yanmei Liao, Lingli Zhu, Min Zhang, Yuhan Wang, Li Liao, Tao Wu, Xueliang Chen, Yingyong Xia, Xue Han Published: 2026 ABSTRACT Tuberculosis remains a leading cause of global mortality, with the rise of multidrug resistant and extensively drug-resistant Mycobacterium tuberculosis strains highlighting an urgent need for novel therapeutics. The mycobacterial cell wall has long served as a validated drug target, owing to its unique architecture comprising arabinogalactan, peptidoglycan, and mycolic acids. This review provides a comprehensive overview of recent advances in cell wall targeting anti tuberculosis drug discovery, encompassing both established and emerging targets within the major biosynthetic pathways. Beyond conventional enzymatic inhibition, a multidimensional framework is explored that includes disrupting cell wall integrity through alternative mechanisms, interfering with energy metabolism and regulatory networks, blocking the secretion and transport of cell wall components, harnessing host-directed therapies and antimicrobial peptides, and leveraging nanotechnology-based delivery systems. By integrating discoveries across these diverse fronts, this review highlights evolving strategies and offers a forward looking perspective on the development of ultra short, highly effective, and resistance proof tuberculosis regimens. Introduction Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the most devastating infectious diseases worldwide. According to the World Health Organization, approximately 10.7 million new cases and 1.23 million deaths were reported in 2024, with TB reemerging as the leading cause of death from a single infectious agent after the COVID-19 pandemic (Zhang Y. et al., 2025; World Health Organization, 2025). Standard first-line regimens comprising rifampicin, isoniazid, pyrazinamide, and ethambutol are effective against drug-susceptible TB. However, their prolonged treatment duration of six to 9 months, coupled with poor patient adherence, has contributed to the alarming rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. Moreover, only a limited number of novel anti TB drugs, including bedaquiline, delamanid, and pretomanid, have been approved in recent decades, highlighting the urgent need for new therapeutic strategies with distinct mechanisms of action to overcome resistance and shorten treatment duration (Zhang Y. et al., 2025; Diab et al., 2025). The mycobacterial cell wall, characterized by its unique and complex architecture, has long been a validated target for anti TB drug discovery. Its three core structural layers, namely, an outer mycolic acid layer, an intermediate arabinogalactan polysaccharide, and an inner peptidoglycan layer, provide not only structural integrity and protection against environmental stress but also contribute critically to Mtb pathogenicity and intrinsic drug resistance (Abrahams and Besra, 2016). Historically, targeting cell wall biosynthesis has proven highly successful, as exemplified by isoniazid, which inhibits InhA in mycolic acid synthesis, and ethambutol, which targets arabinosyltransferases in arabinogalactan assembly. However, the increasing prevalence of drug resistance, driven largely by mutations in target encoding genes such as inhA, katG, and rpoB, has exposed the limitations of strategies focused solely on inhibiting biosynthetic enzymes (Pflégr et al., 2021). Whether mere inhibition of cell wall synthesis is sufficient to achieve rapid and durable bacterial eradication in the era of escalating drug resistance remains an open question. Thus, a multidimensional approach is necessary. Beyond the conventional paradigm of blocking construction, recent advances have unveiled a spectrum of innovative strategies that may be conceptualized as subverting the guardians. These approaches target not only the biosynthetic machinery but also the regulatory networks governing cell wall homeostasis, the transport systems responsible for delivering essential building blocks, the energy metabolism that powers these processes, and the host immune response to enhance bacterial clearance (Kotliarova et al., 2024). In parallel, novel drug delivery systems such as nanoparticles and niosomes have been developed to overcome the formidable permeability barrier of the mycobacterial cell wall, enabling more effective delivery of both existing and new therapeutic agents (El-Ridy et al., 2015; Khatak et al., 2020). The architecture of the Mtb cell wall and the key targets involved in its biosynthesis and transport are shown in Figure 1 (Jiang et al., 2025). This review provides a comprehensive overview of cell wall targeting strategies for tuberculosis treatment. It summarizes the key biosynthetic pathways of arabinogalactan, peptidoglycan, and mycolic acids, along with associated inhibitors, including both established drugs and clinical candidates. Emerging concepts beyond direct inhibition are explored, including disruption of cell wall integrity, interference with energy metabolism and regulatory circuits, blockade of secretion and transport systems, and application of host directed therapies and antimicrobial peptides (AMPs). The potential of nanotechnology based delivery systems to enhance drug penetration and efficacy is also discussed. This review offers a forward looking perspective on exploiting the mycobacterial cell wall to develop next-generation therapies capable of addressing drug resistant tuberculosis by integrating recent advances across these diverse fronts. Mycobacterial cell wall architecture and key drug targets. The cell wall comprises three core layers: outer mycolic acid layer (adapted from (Dulberger et al., 2019; Daffé and Marrakchi, 2019)), intermediate arabinogalactan layer, and inner peptidoglycan layer, overlying the plasma membrane. Key enzymes and transporters are shown at their approximate sites of action. The corresponding gene names are: inhA (InhA), embC (EmbC), dprE1 (DprE1), mmpL3 (MmpL3), pks13 (Pks13), kasA (KasA), mabA (MabA), glfT1 (GlfT1), ugm (UGM), aftB (AftB), murA (MurA), murT/gatD (MurT-GatD), dapB (DapB), murI (MurI), ponA1 (PBP), ldtMt1-3 (Ldt), ripA (RipA), nagA (NagA), lprG (LprG), grcC1 (GrcC1). Color code for target development stages: red, approved/clinical; blue, emerging/preclinical; gray, exploratory. Targeting cell wall biosynthesis Inhibition of arabinogalactan biosynthesis Arabinogalactan is a critical component of the mycobacterial cell wall, providing structural integrity and serving as the anchor for mycolic acids. Its biosynthesis involves a series of essential enzymes, including decaprenylphosphoryl-β-D-ribose2′-oxidase(DprE1) and decaprenylphosphoryl-2-keto-β-D-erythro-pentose reductase (DprE2) for arabinose donor generation, GlfT1 and UGM for galactan chain assembly, and arabinosyltransferases such as EmbC and AftB for arabinan polymerization and terminal modification. Inhibition of these enzymes disrupts cell wall synthesis and has become a major focus of anti-tuberculosis drug development. Inhibitors targeting DprE1 DprE1 is a key enzyme in the arabinogalactan biosynthetic pathway, catalyzing the conversion of decaprenylphosphoryl-β-D-ribose (DPR) to decaprenylphosphoryl-β-D-arabinose (DPA), an essential step for mycobacterial cell wall assembly. Its essentiality and absence in humans have established it as a highly validated target for anti-tuberculosis drug development. Progress has been made in several directions, including the discovery of novel DprE1 inhibitors, structural optimization of existing scaffolds to improve druggability, computational strategies to overcome resistance mutations, and preclinical efficacy studies in clinically relevant animal models. Discovery of novel DprE1 inhibitors The discovery of novel DprE1 inhibitors has become a major focus of anti-tuberculosis drug development, given that DprE1 has emerged as a highly selective and vulnerable target. Through phenotypic screening, a purine lead was optimized to analogues 56 and 64 (MIC 1 μM against H37Rv and resistant strains) (Finger et al., 2023), and the carbostyryl derivative OPC-167832 was validated as a DprE1 inhibitor with exceptionally low MICs (0.00024–0.002 μg/mL) (Hariguchi et al., 2020). Pflégr et al. synthesized N-substituted 5-(3,5-dinitrophenyl)-1,3,4-oxadiazol-2-amine derivatives that exhibited potent activity (MIC ≤0.03 μM) via DprE1 inhibition, leading to accumulation of trehalose monomycolates and dimycolates (Pflégr et al., 2025). Virtual screening identified a quinoxaline ligand with high binding affinity (−10.6 kcal/mol) that restored stability against the C387N mutant (El Haddoumi et al., 2024) and benzimidazole derivatives with compound 21 showing favorable ADMET profiles (Yalcin-Ozkat et al., 2023). However, the quinoxaline ligand has been identified solely through computational approaches and awaits experimental validation. The natural product CNP0123918 as a novel DprE1 binder with reduced toxicity (Snehalatha and Kumar, 2025). Structure-based pharmacophore modeling yielded the azaindole derivative ZINC000170252277 as a non-covalent inhibitor (Kb et al., 2020), while ChEMBL database screening identified C6 with superior binding free energy compared to CT319 (Nir et al., 2021), and hydantoin-based compounds led to ZINC12196803 as a promising non-covalent inhibitor (Mali et al., 2022). Bis-benzothiazole amides optimized from virtual screening exhibited potent activity against drug-resistant strains with binding at Tyr314 (Samoon et al., 2024), and a systematic study of morpholino-pyrimidine inhibitors revealed that MP-38 induced stable folding of the L-I and L-II loops (Tayal et al., 2025). Hybrid molecules were designed and validated to stably engage the active site with low cytotoxicity, including 1,2,3-triazole-benzoxazole (BOK-2, BOK-3) and pyrazole-1,2,4-triazole conjugates (e.g., 7j) (Singh et al., 2024; Ajin et al., 2023). In parallel, the 6-nitropicolinamide derivative 77 demonstrated high oral bioavailability (63%) and covalent binding to Cys387 (Thompson et al., 2026). Optimization of known DprE1 scaffolds Optimizing known DprE1 scaffolds is critical for balancing ultra-high potency with favorable drug-like properties, thereby overcoming the pharmacokinetic and physicochemical limitations that hinder the clinical development of otherwise highly active anti-tuberculosis agents. Based on the benzothiazinone scaffold, Fan et al. introduced a 6-methanesulfonyl substitution and employed five-membered aromatic heterocycles as linkers to modify the aryl side chain, and found that the optimized compounds 6 and 38 exhibited improved aqueous solubility and higher metabolic stability in human liver microsomes compared to the lead compound PBTZ169, while maintaining nanomolar MIC values (47 nM and 30 nM, respectively) against Mtb (Fan et al., 2021). A scaffold hopping strategy was employed to transplant the benzenoid ring of PBTZ169 onto a quinolone nucleus, leading to the synthesis of 22 novel quinolone-benzothiazinone hybrid analogues. Among these, compound 25 retained activity against the DprE1 P116S mutant but showed reduced activity against the C387S mutant, confirming the critical role of the C387 residue in inhibitor binding (Dube et al., 2023). To overcome the poor aqueous solubility of PBTZ169, Shi et al. replaced the 6-trifluoromethyl group with a more hydrophilic methanesulfonyl moiety, leading to the design and synthesis of a series of 6-methanesulfonyl-8-nitrobenzothiazinone derivatives. Among these, MsPBTZ169 and compounds 2 and 8 exhibited MICs below 40 nM against H37Rv along with improved solubility. However, compound 2 showed no detectable plasma concentration after oral administration in mice, underscoring the inherent difficulty in simultaneously optimizing potency, solubility, and pharmacokinetic properties (Shi et al., 2022). Further side chain modification of the benzothiazinone scaffold led to compound 37, which maintained nanomolar activity while achieving significantly improved aqueous solubility and oral bioavailability (70.6%), with in vivo efficacy confirmed in an acute infection mouse model (Fan et al., 2023). Based on the previously identified lead G50, 45 pyrimidinetrione derivatives were designed and synthesized, and compound 42 exhibited a 5-fold increase in DprE1 inhibitory activity compared to G50 along with a high selectivity index (SI = 186.74) surpassing linezolid (Liang et al., 2025). In parallel, structure-activity relationship studies on hydantoin-based DprE1 inhibitors yielded over 80 new derivatives, with optimized compounds achieving submicromolar cellular potency, nanomolar target affinity, balanced physicochemical properties, and low human cytotoxicity, and in vivo activity was validated in an acute tuberculosis infection model (Balabon et al., 2020). Resistance-guided design of DprE1 inhibitors The rational design of next-generation DprE1 inhibitors relies on the elucidation of resistance mechanisms and the application of computational approaches. El Haddoumi et al. performed a virtual screening of 111 molecules with known DprE1 activity and identified six potential lead compounds. Analysis of 10 mutations revealed five as deleterious, including C387N. Subsequent molecular dynamics simulations demonstrated that ligand 2 restored binding stability disrupted by the C387N mutation, as evidenced by a lower RMSD (0.21 nm) and improved hydrogen bonding (El Haddoumi et al., 2024). It was found that a systematic virtual screening of 754 benzothiazinone analogs as irreversible DprE1 inhibitors, incorporating covalent docking and binding free energy calculations, identified three lead compounds (PubChem-155-924-621, PubChem-127-032-794, PubChem-155-923-972) with superior binding affinities (ΔGbinding values of −77.2, −74.3, and −65.4 kcal/mol) compared to PBTZ169 (−49.8 kcal/mol), and molecular dynamics simulations confirmed the structural stability of the complexes over 100 ns (Ibrahim et al., 2024). Additionally, cheminformatics and artificial intelligence analysis of approximately 1300 DprE1 inhibitors revealed marked hydrophobicity and limited chemical diversity, with automatic SAR and R-group decomposition identifying key substructures responsible for activity and machine learning approaches identifying potential toxicophores including thiophene and six-membered aromatic rings (Chhabra et al., 2021). Structure-based pharmacophore modeling of azaindole derivatives, integrating a multi-layered computational platform, identified ZINC000170252277 as a non-covalent DprE1 inhibitor with favorable binding affinity and stability (Kb et al., 2020). A comprehensive computational strategy for hydantoin-based DprE1 inhibitors, combining GA-MLR, atom-based, and field-based 3D-QSAR models, yielded an AAAHR_1 pharmacophore model and identified ZINC12196803 as a lead compound with enhanced binding characteristics (docking score: −9.437 kcal/mol, MMGBSA binding free energy: −70.508 kcal/mol) (Mali et al., 2022). This compound has been identified only in silico and requires experimental confirmation. Systematic investigation of 55 morpholino-pyrimidine-based DprE1 inhibitors using molecular dynamics, docking, 3D-QSAR, and ADMET analysis revealed that MP-38 induced stable folding of the L-I and L-II loops while reducing protein mobility, and a robust 3D-QSAR model demonstrated that negatively charged groups near rings A and B, together with hydrophobic and bulky groups near rings D and E, significantly enhanced inhibitory activity (Tayal et al., 2025). In vivo efficacy and lesion penetration The in vivo efficacy and intralesional pharmacokinetics of DprE1 inhibitors have been extensively evaluated in animal models recapitulating the complex pathology of human tuberculosis. In the C3HeB/FeJ mouse model of caseous necrotic pulmonary lesions, a head-to-head comparison of three clinical candidates (TBA-7371, PBTZ169, and OPC-167832) revealed that lesion penetration and retention at the cellular-caseum interface and caseous necrotic core were critical determinants of efficacy, with OPC-167832 achieving a 3-log10 reduction in lung colony-forming units even at low doses due to its lowest MIC, favorable tissue distribution, and sustained drug concentrations above the MIC at the primary bacterial sites (Robertson et al., 2021). In the same model, the suicide inhibitor BTZ-043 administered as monotherapy for 2 months significantly reduced bacterial burdens in the lungs and spleens. Laser capture microdissection-based pharmacokinetic analysis demonstrated that BTZ-043 penetrated cellular and necrotic lesions and maintained concentrations above the serum-shifted MIC in the caseous necrotic core at the end of the dosing interval (Ramey et al., 2023). In a guinea pig model, BTZ-043 reached high concentrations within Mycobacterium bovis BCG-induced granulomas and, after 4 weeks of treatment, significantly reduced bacterial burdens in the infection site, draining lymph nodes, and spleen, accompanied by fewer and less necrotic granulomas (Eckhardt et al., 2023). Additionally, in a mouse model of chronic tuberculosis, OPC-167832 monotherapy exhibited potent bactericidal activity starting at 0.625 mg/kg, and combinations with delamanid, bedaquiline, or levofloxacin, as well as three- or four-drug regimens centered on delamanid and OPC-167832, showed synergistic effects with superior bacterial burden reduction and relapse prevention compared to standard therapy (Hariguchi et al., 2020). Inhibitors targeting DprE2 The molecular target of the anti-tuberculosis drugs pretomanid and delamanid was identified as DprE2, a key subunit of decaprenylphosphoryl-ribose-2′-epimerase. Through gene overexpression experiments, it was demonstrated that DprE2 overexpression increased mycobacterial tolerance to these drugs by more than 20-fold. Enzymatic assays further revealed that Ddn-activated pretomanid specifically inhibited the conversion of DPR to DPA, with NAD(H) identified as an essential cofactor for drug activation, suggesting that an NAD-adduct may serve as the active metabolite form. DprE2 and DprE1 form a highly druggable enzyme complex. Bicyclic nitroimidazole drugs have achieved irreversible inhibition via NAD-adduct formation, opening avenues for DprE2-targeted inhibitor development and providing a rationale for optimizing existing clinical drugs (Abrahams et al., 2023). Inhibitors targeting galactan biosynthesis enzymes Enzymes involved in galactan biosynthesis represent potential targets for anti-tuberculosis drug development. Galactofuranosyl transferase 1(GlfT1), the initiating enzyme for galactan chain biosynthesis, was systematically evaluated through the construction of knockdown and complemented strains in Mycobacterium tuberculosis H37Ra. Chauhan et al. systematically evaluated GlfT1, the initiating enzyme for galactan chain biosynthesis, using knockdown and complemented strains in Mycobacterium tuberculosis H37Ra. GlfT1 downregulation led to increased susceptibility to ethambutol, reduced biofilm formation, altered cell wall permeability, and significantly impaired bacterial survival in macrophages and in a mouse model, providing the first validation of GlfT1 as an underexplored vulnerable cell wall synthesis target (Chauhan et al., 2023). Moreover, It was found that using the known allosteric inhibitor MS208 as a lead structure, 13 pyrazole and triazole derivatives were designed and synthesized, and their inhibitory activity against UDP-galactopyranose mutase (UGM) was evaluated. The O-acylated derivative DA10 displayed a competitive inhibition mode with a Ki value of 51 ± 4 μM, superior to the lead compound, although no improvement in vitro anti-tuberculosis activity was observed, highlighting the challenge of translating potent enzyme inhibitors into cell-active antibacterial agents (Ahmed et al., 2022). In contrast, three heterocyclic structures were screened as potential UGM inhibitors using docking simulations. An “oxazepino-indole” structure was successfully identified as a novel UGM inhibitor that exhibited in vitro activity against Mtb growth, offering a promising molecular starting point for developing novel anti-tuberculosis drugs targeting this bacteria-specific enzyme (Maaliki et al., 2020). Inhibitors targeting arabinosyltransferases Arabinosyltransferases represent important targets for disrupting the assembly of arabinogalactan and lipoarabinomannan in the mycobacterial cell wall. It was found through molecular docking studies that the binding affinities of ethambutol, isoniazid, and five ethambutol-modified derivatives with Mycobacterium tuberculosis arabinosyltransferase C (EmbC) were evaluated. The modified molecules Emb1 and Emb3 exhibited superior binding energies (−5.77 kcal/mol and −5.13 kcal/mol, respectively) compared to the parent compound ethambutol, indicating their potential as promising EmbC inhibitors (Das et al., 2020), although these computational predictions await experimental validation. The high-resolution cryo-EM structures of the mycobacterial glycosyltransferase AftB were determined in its apo state and in complex with the donor substrate analog 2F-FPA, and it was shown that AftB adopts a GT-CA fold with its transmembrane and periplasmic domains forming an irregular tube-shaped cavity that serves as the critical region for substrate binding and catalysis. Furthermore, through integration of biochemical experiments with molecular dynamics simulations, the catalytic residue D62 and key substrate-binding residues including R221 and R372 were identified, and a double-displacement mechanism was proposed for the formation of β-(1→2) arabinosidic linkages (Liu Y. et al., 2025). To systematically investigate the structural requirements of ethambutol, three series of novel analogs were designed and synthesized, including analogs retaining the ethylenediamine scaffold with fluorine substitution or phenyl ring modifications, as well as “reversed” analogs with exchanged nitrogen and oxygen atom positions. It was demonstrated that only analogs highly similar to ethambutol in structure, such as compound 2 with side chain ethyl groups replaced by methyl groups, exhibited comparable anti-tuberculosis activity, while fluorine substitution, phenylring modifications, or atom position exchange led to reduced or complete loss of activity, highlighting the highly conserved structural requirements of ethambutol (Abdelaziz et al., 2025). Inhibition of peptidoglycan biosynthesis Peptidoglycan is an essential component of the mycobacterial cell wall, providing structural integrity and protection against osmotic lysis. Its biosynthesis involves a complex pathway encompassing precursor synthesis in the cytoplasm, lipid-linked intermediate assembly at the membrane, and extracellular cross-linking and remodeling. Given its essentiality and the absence of many of its biosynthetic enzymes in humans, the peptidoglycan pathway has long been recognized as a fertile ground for anti-tuberculosis drug development. Recent advances have expanded the repertoire of potential targets within this pathway, ranging from early-stage enzymes (MurA, MurT-GatD, DapB, MurI) involved in precursor generation and modification, to later-stage players including L,D-transpeptidases, penicillin-binding proteins, and DacB1 that mediate cross-linking and cell wall maturation. In addition, emerging evidence has highlighted the importance of peptidoglycan hydrolases (RipA, Ami1, NlpC_P60 family) in cell division and remodeling, as well as recycling pathways (NagA) and interconnected metabolic nodes (MtPrsA) as novel vulnerabilities. Inhibitors of precursor synthesis and modification Targeting the early steps of peptidoglycan precursor synthesis and modification is a critical strategy for developing novel anti-tuberculosis agents. Computer-aided drug design approaches identified four peptidomimetic compounds as potential inhibitors of MurA, the key transferase catalyzing the initial step in peptidoglycan biosynthesis. Molecular dynamics simulations confirmed their stable binding with catalytic site residues of MurA and favorable pharmacokinetic profiles (Kumar et al., 2020). It was established that D-glutamate amidation in peptidoglycan precursors is essential. Knockdown of the MurT-GatD complex via CRISPR interference was found to be lethal, causing severe growth defects, reduced peptidoglycan cross-linking, and increased sensitivity to lysozyme and β-lactam antibiotics, thereby identifying MurT-GatD as a novel and vulnerable drug target (Shaku et al., 2023). Additionally, the Rv3712 and Rv3713 genes form an operon encoding the MurT/GatD enzyme complex. Rv3712 possesses ATPase activity and forms a heterodimer with Rv3713 that interacts with cell division and regulatory proteins, further validating MurT/GatD as a novel anti-tuberculosis drug target (Maitra et al., 2021). Angrish et al. validated dihydrodipicolinate reductase (DapB) as an essential target by constructing a dapB antisense knockdown mutant, and identified a lead compound B59 through virtual screening of approximately 95,000 compounds. This compound demonstrated effective inhibition of DapB enzymatic activity (IC50 11 μg/mL) and anti-mycobacterial activity (MIC99 20 μg/mL) with no significant cytotoxicity (Angrish et al., 2023). The anti-tubercular potential of natural flavonoids (naringenin and quercetin) was investigated as inhibitors of glutamate racemase (MurI), and it was found that these flavonoids effectively bound to the active site of MurI, significantly inhibited its racemization activity (competitive inhibition with Ki values of 23.8 µM and 20.8 µM, respectively), and disrupted mycobacterial membrane integrity, confirming their mechanism of action through interference with peptidoglycan biosynthesis (Pawar et al., 2020). Inhibitors of cross-linking and remodeling Enzymes responsible for peptidoglycan cross-linking and remodeling have also emerged as promising targets. The inhibitory activities of β-lactam antibiotics and LdtMt2 inhibitors against L,D-transpeptidases and penicillin-binding proteins were systematically evaluated using fluorescent peptide probes, and it was revealed that dual targeting of L,D-transpeptidases(Ldts) and penicillin-binding proteins(PBPs) was necessary for achieving effective anti-mycobacterial activity, with Ldt inhibition showing a stronger correlation with bacterial growth suppression (de Munnik et al., 2025). Furthermore, The systematic evaluation of β-lactam antibiotics combined with β-lactamase inhibitors demonstrated that carbapenems (imipenem, meropenem, tebipenem) form stable acyl-enzyme complexes with the D,D-carboxypeptidase DacB1, with imipenem showing the fastest binding kinetics,and that the addition of β-lactamase inhibitors further enhances efficacy (Nantongo et al., 2025). Moreover, the diazabicyclooctane durlobactam was demonstrated to significantly enhance the efficacy of β-lactam antibiotics against M. abscessus through a dual mechanism, acting as a potent inhibitor of the β-lactamase BlaMab while also directly inhibiting key peptidoglycan synthesis enzymes including L,D-transpeptidases and D,D-carboxypeptidase, with triple combinations showing exceptionally potent in vitro activity (Dousa et al., 2022). Durlobactam was further shown to function as a dual inhibitor in Mtb, targeting both the BlaC β-lactamase and key peptidoglycan transpeptidases (PonA1, LdtMt1, LdtMt2, LdtMt3), with biochemical assays and mass spectrometry confirming the formation of stable acyl-enzyme complexes and antibiotic susceptibility testing revealing intrinsic activity against Mtb isolates as well as significant potentiation of β-lactam efficacy (Nantongo et al., 2024). Healy et al. characterized the critical roles of two peptidoglycan hydrolases, RipA and Ami1, revealing that RipA serves as the major hydrolase for cell division. Its depletion led to elongated multiseptated chains and increased susceptibility to cell wall-targeting antibiotics, while Ami1 was found to be crucial for persistence during chronic infection, demonstrating partial functional redundancy yet distinct roles at different stages of infection (Healy et al., 2020). It was comprehensively reviewed that the NlpC_P60 peptidase family in mycobacteria comprises five domain-containing proteins (RipA, RipB, RipC, RipD, and RipE), with RipA and RipB playing critical but non-redundant roles in cell division, RipC involved in maintaining cell wall integrity, and RipE associated with biofilm formation and drug resistance, representing underexplored anti-mycobacterial drug targets (Do et al., 2025). Inhibitors of recycling and metabolism Peptidoglycan recycling and associated metabolic pathways have emerged as novel intervention points. A NagA gene deletion mutant was analyzed with multiple complementary approaches, which identified NagA as the sole enzyme responsible for the deacetylation of N-acetylglucosamine-6-phosphate in mycobacteria. Loss of NagA led to altered peptidoglycan cross-linking, thickened cell wall, and significantly increased susceptibility to multiple cell wall-targeting agents, revealing the NagA-mediated peptidoglycan recycling pathway as a potential drug target (Guy et al., 2025). Furthermore, three phytocompounds (hesperidin, rebaudioside A, and rutin) were identified as novel inhibitors of Mtb phosphoribosyl pyrophosphate synthetase (MtPrsA) through systematic screening, molecular docking, and molecular dynamics simulations. Enzyme inhibition assays confirmed their inhibitory activity with distinct mechanisms, establishing MtPrsA as a viable drug target (Manthattil Vysyan et al., 2024). Inhibition of mycolic acid biosynthesis Mycolic acids are long-chain fatty acids that form an essential component of the mycobacterial cell envelope, contributing to its impermeability and virulence. Their biosynthesis involves a complex pathway encompassing the fatty acid synthase I(FAS-I) system for precursor synthesis, the fatty acid synthase II(FAS-II) system for chain elongation, and numerous modifying and transporting enzymes. Given their essentiality and uniqueness to mycobacteria, enzymes within this pathway have long been validated targets for anti-tuberculosis therapy. Recent advances have expanded the repertoire of inhibitors targeting these enzymes, ranging from the Ag85 complex and InhA to MabA, KasA, Pks13, and FadD32, among others. Inhibitors targeting the Ag85 complex The Ag85 complex, comprising Ag85A, Ag85B, and Ag85C, catalyzes the transfer of mycolic acids to the cell wall, representing a critical late-stage step in mycolic acid assembly. Amino-pyrazoline derivatives were discovered as a novel class of dual-function anti-tuberculosis agents, and lead compounds AP-02 and AP-05 were optimized to show enhanced efficacy against mycobacteria, with mechanistic studies identifying Ag85C as their primary target, thereby disrupting late-stage mycolic acid biosynthesis and impairing cell wall integrity (Cui et al., 2025). A series of oxadiazolone-core derivatives were evaluated for antibacterial activity against Mycobacterium abscessus, with iBpPPOX identified as the most potent compound. Activity-based protein profiling combined with mass spectrometry revealed that iBpPPOX forms a covalent adduct with the catalytic serine residue of Ag85C, identifying it as a primary vulnerable target (Madani et al., 2020). The structural dynamics of Ag85C following covalent inhibition by the β-isomer monocyclic enolphosphorus compound Cycliphostin (CyC8β) were investigated by bioinformatics and molecular dynamics simulations. Covalent binding to the catalytic serine 124 residue induced significant structural instability and flexibility in Ag85C, particularly in key loops L1 and L2, thereby identifying potential hot spots for structure-based design of novel irreversible inhibitors (Adewumi et al., 2022). Inhibitors targeting InhA InhA (enoyl-acyl carrier protein reductase) is a key enzyme in the FAS-II elongation cycle and the well-established target of isoniazid. Several prodrug-type inhibitors requiring KatG activation have been reported. Mutual esters of 2-(2-isonicotinoylhydrazineylidene)propanoic acid and twenty related propanamide analogs showed excellent activity against drug-sensitive and multidrug-resistant Mtb via InhA targeting (Pflégr et al., 2021). Four pyridine carboxamide analogs from phenotypic screening also depended on KatG activation, with resistance to two linked to novel katG mutations that do not confer cross-resistance to isoniazid (Chengalroyen et al., 2020). Direct InhA inhibitors have been developed through various design strategies. Mubarak et al. demonstrated that diaryl ether dehydrozingerone derivatives (7, 14) exhibited bactericidal activity (MBC 4 and 8 μg/mL) and bound to wild-type and mutant InhA, with activity against isoniazid-resistant and MDR isolates (Mubarak et al., 2025). A 1,5-triazole bis-triclosan derivative (2) showed IC50 5.6 µM against InhA, and compound 11 gave MIC99 12.9 µM in M. bovis whole-cell assays (Armstrong et al., 2020) 1,2,4-triazole-based compounds (6h,6i,6l,11c) had IC50 1.3–4.7 µM and activity against MDR/XDR strains (Zawal et al., 2023). A diphenyl ether-pyrazoline hybrid (PYN-8) showed MIC 4–7 μM with a Tyr158 hydrogen bond and π-π stacking with NAD+ (Tiwari et al., 2020). Computational approaches identified further leads. An integrated machine-learning and pharmacophore screen yielded JFD01724 (Kuldeep et al., 2021). A cheminformatics screen of the ASINEX database gave B244, B369, and B310 as potential inhibitors of isoniazid-resistant strains (Kamera et al., 2024). A 3D-QSAR/pharmacophore model based on 47 compounds led to pyrazole derivatives (5a,5c,5d,5e) with MICs 2.23–4.61 µM (Modi et al., 2023). SAR optimization of the KES4 A-ring produced two improved candidates (3d,3f) (Taira et al., 2020). Finally, in a nutrient starvation model, all tested InhA inhibitors (including diazaborine derivatives AN12855, AN12541) reduced viability of non-replicating Mtb by more than 3 logs over 21 days, confirming that InhA is an effective target even in non-replicating populations (Flint et al., 2020). Inhibitors targeting other FAS-II enzymes Beyond InhA, other enzymes within the FAS-II elongation cycle represent additional drug targets. A large-scale virtual screening of 1,792,771 compounds against MabA (FabG1) identified 48 novel lead compounds from five distinct classes, with 47 compounds showing MM/PBSA binding free energies significantly higher than the only previously reported MabA inhibitor (Panda et al., 2026). All these compounds have been identified only in silico and no experimental validation has been reported. Fragment-based screening using a novel LC-MS/MS assay discovered the first specific small-molecule MabA inhibitors. An anthranilic acid fragment was optimized into more potent inhibitors, and binding was confirmed by 19F ligand-observed NMR (Faïon et al., 2020). Structure-based virtual screening against KasA identified six top-ranking compounds that bound strongly to the malonyl site, with computed binding free energies significantly lower than the reference KasA inhibitor TLM5 (Andrianov et al., 2025). These computational predictions require experimental confirmation. A computational screen of 730 molluscan metabolites using docking, ADMET prediction, and molecular dynamics identified four compounds (CMNPD7125, CMNPD22991, CMNPD4542, and CMNPD12265) as potential KasA inhibitors, which exhibited favorable ADMET profiles and stable protein-ligand binding over 200 ns simulations (Alanzi et al., 2025), but these are purely computational predictions without experimental validation. KEGG pathway analysis identified mtFabH as a key regulatory enzyme. Structure-based virtual screening of the ChEMBL library yielded two lead compounds, ChEMBL414848 (C1) and ChEMBL363794 (C2), with superior docking scores to thiolactomycin, and molecular dynamics showed that C2 had the lowest binding free energy (Kumar et al., 2022). Structure-based virtual screening of the NPASS natural product library identified three novel FabD inhibitors, among which NPC313985 exhibited the most stable interaction with FabD in molecular dynamics simulations, thereby disrupting mycolic acid biosynthesis (Sundararajan et al., 2024). Inhibitors targeting Pks13 Polyketide synthase 13 (Pks13) catalyzes the final condensation step in mycolic acid biosynthesis, an essential process for mycobacterial cell wall assembly. Trehalose-Pks13 inhibitor conjugates constructed via click chemistry demonstrated that trehalose modification enhanced anti-mycobacterial potency, validating the “Trojan Horse” strategy for overcoming cell wall permeability (Kumbalathara et al., 2025). The covalent compound CMX410 irreversibly targets the acyltransferase domain of Pks13 through a β-lactam, showing high potency against clinical isolates and oral bioavailability (Krieger et al., 2025). BMVC-8C3O was found to inhibit Pks13 via binding confirmed by surface plasmon resonance and molecular docking. Mutations of Asn1640 and Ser1533 reduced its binding affinity (Liu T. et al., 2025). Phenotypic screening identified a pentafluorophenyl warhead lead that targets Pks13. Optimization yielded compound 43 with improved metabolic stability while retaining activity, confirming Pks13 as a drug target (Green et al., 2025). Coumestan derivatives were identified as a novel class of Pks13 inhibitors. Lead compound 1 showed potent bactericidal activity, dose-dependent efficacy in mice, synergy with rifampin, and favorable bioavailability (Lun et al., 2023). A scaffold hopping strategy produced 2,4,5-substituted benzoxazole derivatives with potent in vitro activity, low cytotoxicity, and on-target effects mapped to the Pks13 thioesterase domain (Obadawo et al., 2025). An integrated computational screen of the Asinex library identified three leads (BBB_26582140, BBD_30878599, BBC_29956160) targeting the Pks13 thioesterase domain, with 300 ns MD simulations confirming stable complex formation (RMSD ≤3 Å) and favorable pharmacokinetic profiles (Altharawi et al., 2023). Inhibitors targeting other mycolic acid-related enzymes Several other enzymes involved in mycolic acid modification and activation have also been targeted. Compounds 6c and 6i from a series of 2-[(2-amino-6-methylpyrimidin-4-yl)sulfanyl]-N-arylacetamide derivatives exhibited anti-tuberculosis activity threefold more potent than ethambutol, with docking studies suggesting selective binding to cyclopropane mycolic acid synthase 1 (CmaA1) (Erkin et al., 2023). Mtb epoxide hydrolase EphD was confirmed as a target of urea and thiourea derivatives. The isoniazid analog isoxyl and the MmpL3 inhibitor AU1235 significantly inhibited EphD activity, and mycolic acid profile analysis confirmed inhibition within bacterial cells (Madacki et al., 2021). Nitroimidazole oxazine derivatives targeting the deazaflavin-dependent nitroreductase (Ddn) were analyzed using 3D-QSAR, docking, and molecular dynamics, yielding CoMFA and CoMSIA models with good predictive ability. Key residues (Tyr65, Ser78, Tyr130, Tyr133, Tyr136) contributed significantly to binding energy, guiding rational design (Yang et al., 2025). The isoxazole derivative M1 specifically inhibited fatty acyl-AMP ligases FadD32 and FadD28, regulated cell wall synthesis genes, and reduced bacterial burden and granulomas in infected macrophages and a mouse chronic infection model (Rani et al., 2025). High-throughput screening of the Prestwick Chemical Library identified the salicylanilide closantel as a potent FadD32 inhibitor, with direct binding confirmed by thermal shift assays and docking, IC50 7.7 µM, and MIC 0.08 µM against Mtb (Le et al., 2022). Whole-cell phenotypic screening identified azetidine derivatives (BGAz) that disrupt cell envelope biogenesis by targeting late stages of mycolic acid biosynthesis through a mechanism distinct from existing inhibitors (Cui et al., 2024). A 1,3-diarylpyrazolyl-acylsulfonamide hit from phenotypic screening in cholesterol-containing medium exerted bactericidal activity by disrupting cell wall biosynthesis via a novel mechanism distinct from MmpL3, DprE1, InhA, and EthA (Khonde et al., 2021). Inhibitors targeting MmpL3 MmpL3 is a mycolic acid transporter that plays a critical role in the translocation of trehalose monomycolates across the inner membrane. Discovery and optimization of MmpL3 inhibitors Several screening campaigns have identified diverse chemical scaffolds targeting MmpL3. A focused library of 400 synthetic compounds yielded novel phenyl urea derivatives with sub-micromolar activity. Chemical proteomics identified MmpL3 along with EphD and EphF as targets, and structural optimization produced a lead with enhanced activity, low cytotoxicity, improved solubility and oral bioavailability (Mostert et al., 2025). Among dihydrosphingosine and ethambutol analogs, 11 compounds showed good activity. Lead 12b was confirmed to target MmpL3, exhibiting far greater potency than ethambutol, with killing that is dependent on time and concentration, and synergy with rifampicin (Linhares et al., 2023). Re-evaluation of 2,5,6-trisubstituted benzimidazoles by bacterial cytological profiling revealed cell wall damage and ATP accumulation, clarifying that these compounds target MmpL3 rather than cell division (Zhang M. et al., 2025). Thienopyrimidine amide analogs were also confirmed to target MmpL3, inducing cell wall stress and characteristic ATP elevation (Baldin et al., 2025). Computational approaches have further accelerated inhibitor discovery and optimization. Structure-based high-throughput virtual screening combined with molecular dynamics identified four inhibitors (C1, C3, C7, C9) from approximately 17 million compounds. These compounds occupy the proton channel and disrupt key aspartate-tyrosine pairs (D256-Y646 and D645-Y257), thereby blocking mycolic acid precursor transport (Choksi et al., 2024). A pharmacophore-based computational workflow employing SQ109 as a lead yielded two candidates (ZINC000000016638, ZINC000000003594), with the former showing superior stability in MD simulations (C et al., 2023). Fifty pyrazole amide derivatives were designed and synthesized. Compounds 15 and 35 exhibited potent activity against drug-sensitive and resistant strains, and docking, molecular dynamics, and genetic analysis of SQ109-resistant strains confirmed MmpL3 targeting (Maddipatla et al., 2025). Fifty adamantane and adamantanol indole-2-carboxamides were also prepared. Compounds 8j and 8k showed excellent activity, with docking revealing a binding mode similar to ICA38 and AU1235, occupying the S3-S5 subsites and disrupting Asp-Tyr proton relay pairs (Alsayed et al., 2021). The arylsulfonamide TPN-0157345 was shown to target MmpL3 via bacterial cytological profiling (morphological changes similar to AU1235), iniB induction, ATP elevation, and low-level resistance in a strain carrying the S591I mutation (Allen et al., 2024). In addition to directly targeting MmpL3, the inhibitor SQ109 has been reported to exert its bactericidal effect primarily through respiration inhibition. Using the computational tool DECIPHAER, Johnson et al. revealed that SQ109 kills M. tuberculosis mainly by disrupting energy metabolism rather than its previously known cell-wall effects, a finding confirmed by ATP assays and cell survival experiments. Thus, SQ109 may have a dual mechanism of action involving both MmpL3 inhibition and respiratory chain disruption (Johnson et al., 2025). Collectively, these studies have greatly expanded the chemical diversity of MmpL3 inhibitors and provided optimized leads with improved drug-like properties. Structural insights into MmpL3 inhibition A structure-based design approach was employed to develop a series of novel compounds targeting MmpL3, and the lead molecule ST004 exhibited potent inhibitory activity against Mtb in cell culture, with cryo-electron microscopy resolving the complex structure of ST004 bound to MmpL3 within lipid nanodiscs, revealing that ST004 binds to the inhibitor-binding pocket within the proton translocation channel with critical roles played by the S4 and S5 subsites (Hu et al., 2022). Resistance mechanisms and pharmacological characterization The S288T mutation in MmpL3 was investigated using molecular dynamics and quantum mechanics simulations, revealing that it induces local conformational changes in the periplasmic channel, rotates residue Y44, and causes pronounced channel bending, thereby reducing substrate transport efficiency and conferring resistance to SQ109 (Ge et al., 2024). Sequential selection of resistant mutants against structurally diverse MmpL3 inhibitors showed that all resistant isolates carried mmpL3 mutations, with multiple substitutions (e.g., F255L, L567P, V646M, F644I/L) accumulating under increasing pressure, leading to higher resistance levels and broader cross-resistance without a fitness cost (McNeil et al., 2020). A systematic comparison of eleven MmpL3 inhibitor series revealed common microbiological properties, including potent activity against replicating Mtb, enhanced efficacy against intramacrophage bacilli, rapid bactericidal action, and cell wall stress accompanied by increased ATP levels, while being inactive against dormant bacilli (Ames et al., 2025). Berube et al. investigated the kill kinetics of NITD-349 and found significant inoculum dependence, achieving rapid sterilization at low bacterial densities but reduced kill rates at high densities. Combination with isoniazid synergistically enhanced killing and prevented the emergence of resistant mutants (Berube et al., 2023). Overall, these findings delineate the resistance landscape and pharmacological profile of MmpL3 inhibitors, thereby guiding strategies to circumvent resistance and optimize treatment regimens. As shown in Figure 2 (Jiang et al., 2025), a conceptual framework integrates conventional and innovative cell wall-targeting strategies, including disruption of integrity, energy metabolism regulation, blocking secretion, host-directed therapy, and nanodelivery. Multidimensional modulation of the mycobacterial cell wall. The inner ring summarizes traditional strategies targeting biosynthetic enzymes of mycolic acids, arabinogalactan, and peptidoglycan. The outer ring highlights five emerging approaches with their representative targets/molecules: disruption of cell wall integrity (green), energy metabolism and respiration (blue), blocking secretion and transport (orange), host-directed therapy and AMPs (red), and nanotechnology-based delivery (purple). Disruption of cell wall integrity Diverse mechanisms have been implicated in the disruption of mycobacterial cell wall integrity. Knoll et al. employed a GC × GC-TOFMS metabolomics approach and revealed that the decoquinate derivative RMB041 caused significant metabolic alterations in fatty acid, amino acid, glycerol metabolism, and the urea cycle, with accumulation of fatty acids (e.g., C10:0–C20:0, Δ9 C16:1, Δ9 C18:1) and precursors such as glycerol-3-phosphate and myo-inositol, indicating that RMB041 primarily disrupts mycobacterial cell wall biosynthesis (Knoll et al., 2021). Among polycyclic amine derivatives, compounds 14 and 15 exhibited strong activity against Mtb H37Rv, and a PiniB-LUX reporter assay showed they caused early and sustained cell wall damage similar to ethambutol (Kapp et al., 2021). Heterologous expression of the PE_PGRS47 protein in Mycobacterium smegmatis altered colony morphology, cell wall lipid composition, and increased permeability, leading to enhanced susceptibility to multiple antibiotics and stressors (Li et al., 2023). Eight new arenicolide macrolides (Ar-D to Ar-K) were isolated from Micromonospora sp. GR10. Ar-A displayed potent bactericidal activity against MDR/XDR Mtb through ATP depletion and cell wall disruption, reduced bacterial burden and pulmonary pathology in zebrafish and mouse models, and showed efficacy against intracellular bacteria (Hwang et al., 2025). It was demonstrated that three tanshinones (tanshinone I, IIA, cryptotanshinone) from Salvia miltiorrhiza exhibited MIC90 values of 0.38–1.21 μg/mL against drug-resistant strains with low cytotoxicity, while scanning electron microscopy revealed morphological cell wall changes and resistant mutants harbored mutations in PE_PGRS genes, suggesting the cell wall as a target (Polinário et al., 2025). A 39-amino acid peptide (RapTB, from hemoglobin β chain HBB 112-147) identified from a human lung peptide library exerted bactericidal activity against extracellular Mtb by disrupting cell wall integrity, with low toxicity to primary human macrophages (Klevesath et al., 2025). Thus, disrupting cell wall integrity via multiple mechanisms offers a promising strategy to overcome drug-resistant tuberculosis. Metabolic and energy regulation of cell wall synthesis Mycobacterial cell wall synthesis is tightly coupled to energy metabolism and regulatory networks, rendering these interconnected pathways attractive targets for anti-tuberculosis drug development. Energy metabolism and respiration The energy metabolism and respiratory chain of Mtb are essential for bacterial survival and represent critical vulnerabilities for therapeutic intervention. The crystal structure of mycobacterial malic enzyme (MEZ) was resolved, revealing that MEZ exists as a flexible dimer capable of alternating between open and closed conformations. This structural plasticity provides a foundation for designing selective inhibitors that exploit differences between MEZ and human malic enzymes, thus linking central carbon metabolism to redox balance and energy supply (Burley et al., 2021). Targeting the respiratory chain, the novel candidate Sudapyridine (WX-081), a pyridine analog of bedaquiline, showed comparable in vitro efficacy against drug-sensitive and drug-resistant Mtb while exhibiting weaker hERG channel inhibition and no QTc prolongation in beagle dogs, indicating reduced cardiotoxicity (Yao et al., 2022). Another key agent, The mycobacterial cytochrome b subunit (QcrB) within the cytochrome bc1 complex was inhibited by another key agent, Telacebec (Q203), thereby disrupting menaquinol-driven electron transport and ATP production (Malík et al., 2021). Furthermore, the biosynthesis of virulence lipids PDIM and PGL was downregulated by Q203, thereby sensitizing Mtb to other antibiotics such as vancomycin and rifampicin (Zhou et al., 2023). Similarly, a series of imidazo[1,2-a]pyridinecarboxamide derivatives (compounds 15 and 16) were designed to target QcrB, leading to inhibition of electron transport and proton translocation, and they maintained potent activity against multidrug-resistant and extensively drug-resistant clinical isolates (Onajole et al., 2020). Collectively, these findings underscore that disrupting energy metabolism and respiration, either through direct enzyme inhibition or by targeting the electron transport chain, constitutes a highly effective strategy against drug-resistant tuberculosis. Regulation and signaling Signaling and regulatory networks governing cell division, metabolism, and cell wall homeostasis are key anti-tuberculosis targets. A multi-level computational screen of three large libraries identified potential inhibitors of Mtb serine/threonine protein kinase B (PknB), yielding six lead compounds including Riboflavin Monophosphate and Tedizolid Phosphate. One compound (AB-00011214) induced a shift of the active site from a closed to an open conformation (Vieira et al., 2021). The transcription factor BlaI (Rv1846c) was found to regulate cell division and β-lactam susceptibility. Its overexpression delayed growth, caused cell elongation and multi-septum formation, altered cell wall lipid permeability, and increased sensitivity to β-lactams by directly repressing the key division gene ftsQ (Xu et al., 2025). Deletion of the surface adhesins MTP or HBHA altered expression of genes involved in the tricarboxylic acid cycle, oxidative phosphorylation, and cell wall transport. ATP synthase genes were upregulated but intracellular ATP levels dropped, suggesting impaired proton motive force or increased ATP consumption (Naidoo et al., 2025). Finally, the allosteric regulation of the cell wall hydrolase RipA was elucidated: the activator protein SteB forms a homodimer that engages the RipA coiled-coil domain, while the cytoplasmic domain of SteA may sense cell wall metabolic status via phosphonucleotide binding, thereby transducing regulatory signals (Carloni et al., 2025). Together, these findings highlight that targeting signaling kinases, transcription factors, adhesins, and allosteric regulators can disrupt the coordinated networks governing mycobacterial cell wall synthesis and division. Multi-mechanism and computational approaches Integrated computational and experimental strategies have uncovered diverse mechanisms of action and enabled rational inhibitor design. A synthetic-bioinformatic approach predicted structures from 96 nonribosomal peptide synthetase gene clusters and chemically synthesized 157 cyclic peptides, leading to nine new antibiotics with varied modes of action, including inhibition of cell wall biosynthesis (SyCPA 4) and disruption of membrane integrity (SyCPA 12/102/123) (Chu et al., 2020). Furthermore, ab initio fragment molecular orbital calculations elucidated key interactions of a benzimidazole derivative (compound 7) with InhA, showing hydrogen bonds and electrostatic contacts with Gln100 and Ala157. Structure-based design of 24 analogues identified N2-OH (with a hydroxyl at the R2 position), which formed new hydrogen bonds and electrostatic interactions with Ile215 and NAD+, yielding the highest total interaction energy (−118.2 kcal/mol) (Pornprom et al., 2025). These examples illustrate how multi-mechanism discovery and computational approaches synergistically advance anti-tuberculosis drug development. Other cell wall-associated transport and secretion proteins The transport of mycolic acids and other cell wall components across the mycobacterial cell envelope is essential for cell wall assembly and integrity. Targeting the proteins that mediate these processes has emerged as a highly effective strategy for anti-tuberculosis drug development. Additional proteins involved in lipid transport and cell wall assembly have also been explored as drug targets. Computational virtual screening identified a series of dimethylaminophenyl hydrazide small molecules that bind to the mycobacterial lipid transport protein LprG with moderate micromolar affinity, as confirmed by a fluorescent competitive binding assay. These compounds inhibit mycobacterial growth in an LprG-dependent manner, and a mutation (F123) in the LprG binding cavity conferred resistance to the potent compound LB04, thereby validating LprG as a druggable target (Bai et al., 2020). A novel resistance mechanism mediated by the previously uncharacterized polyprenyl diphosphate synthase GrcC1 was uncovered, wherein a specific A132V mutation in GrcC1 conferred low-level resistance to a broad spectrum of drugs across multiple mycobacterial species. Functional studies showed that GrcC1 overexpression decreased drug susceptibility and reduced cell wall permeability, whereas gene silencing or knockout increased permeability and drug sensitivity, establishing GrcC1 as a critical modulator of the cell wall barrier and a potential target for reversing intrinsic resistance (Fang et al., 2025). Additionally, CRISPR-Cas12-based silencing of the highly conserved MSMEG_0311 gene caused severe growth defects and altered colony morphology. The protein product localizes preferentially to the cell pole and influences polar growth. Permeability assays, drug susceptibility tests, and transcriptomic analysis confirmed its cell wall-associated function, particularly affecting expression of iniA and the sigF regulon. Thus, MSMEG_0311 is proposed as a novel drug target (Sodani et al., 2024). Thus, targeting alternative transport and secretion proteins expands the arsenal of anti-tuberculosis agents. Other mechanisms and emerging strategies In addition to the major cell wall biosynthesis pathways, several other targets and strategies have emerged that offer novel approaches for anti-tuberculosis drug development. These include regulatory networks controlling cell wall synthesis, unconventional enzymes involved in cell wall assembly, immunomodulatory approaches, and drug delivery strategies. Regulation of cell wall synthesis and division Transcriptional and allosteric regulators critically control cell wall synthesis and division in Mtb. The transcription factor BlaI (Rv1846c) was found to regulate cell division and β-lactam susceptibility. Its overexpression delayed growth, caused cell elongation and multi-septum formation, altered cell wall lipid permeability, and increased sensitivity to β-lactams by directly repressing the key division gene ftsQ (Xu et al., 2025). The allosteric regulation of the cell wall hydrolase RipA was elucidated through structural and biochemical studies. The activator protein SteB forms a homodimer and engages the RipA coiled-coil domain in an induced-fit manner, while the cytoplasmic domain of SteA may function as a phosphonucleotide-binding protein that senses cell wall metabolic status and transduces regulatory signals (Carloni et al., 2025). Moreover, the LytR_C domain-containing protein VirR participates in linking peptidoglycan to arabinogalactan via interaction with LCP family proteins (e.g., Lcp1). Deletion of virR led to structural cell wall abnormalities and enhanced extracellular vesicle production, revealing a link between cell wall remodeling and vesicle biogenesis (Salgueiro-Toledo et al., 2025). Overall, the coordinated networks governing mycobacterial cell wall synthesis and division can be disrupted by targeting transcription factors, hydrolase regulators, and cell wall-linkage proteins. Novel targets in cell wall synthesis Several unconventional targets beyond the classical pathways have been identified. A virtual screening of the Super Natural-II database against RmlD identified ligand-567 as a potential inhibitor, which forms hydrogen bonds with key active site residues (Asp-105, Val-158, Thr-160, Gly-161, Arg-224, Arg-256) (Ravichandran et al., 2022). The aromatic diterpenoid ebractenoid F from Euphorbia ebracteolata was found to inhibit the acetyltransferase activity of the bifunctional enzyme GlmU by competitively blocking acetyl-CoA binding and interacting with residue Ala434, exhibiting an MIC of 12.5 mg/mL against Mtb H37Ra and synergy with isoniazid (Han et al., 2022). The TB drug candidate SQ109 and its analogues were shown to act as uncouplers of the proton motive force. More importantly, cell wall biosynthesis was directly inhibited by these compounds via targeting the recycling of the essential lipid carrier decaprenyl phosphate, as confirmed by the observation that exogenous undecaprenyl phosphate rescued bacterial growth (Malwal et al., 2023). Finally, Huang et al. demonstrated that compound ACA (3-azidothiophene-2-carboxylic acid) killed Mtb by binding to the cell wall core assembly proteins CpsA1 and CpsA2, thereby inhibiting their pyrophosphatase activity and blocking arabinogalactan-peptidoglycan ligation. Resistance was mapped to a V221E mutation in the cpsA2 gene (Hu et al., 2025). Thus, the druggable target landscape within mycobacterial cell wall synthesis has been substantially broadened. Chemical synthesis and immunomodulatory strategies Chemical synthesis of cell wall glycans not only enables structural studies but also provides defined immunomodulatory agents that can fine-tune host immune responses against Mycobacterium tuberculosis. An orthogonal one-pot glycosylation strategy based on glycosylortho-(1-phenylvinyl) benzoates was developed, enabling the efficient chemical synthesis of the complex arabinogalactan 92-mer and its fragments (14-mer, 30-mer, 50-mer) from the Mtb cell wall. It was revealed by conformational analysis using molecular dynamics simulations and NMR spectroscopy, along with immunological studies in human cell models, that the surface-exposed 30-mer epitope induced only modest NF-κB activation while preserving cell viability (Ma et al., 2025). In a separate approach, rabbits were immunized with Mtb H37Rv cell wall components. Novel polyclonal antibodies against lipoarabinomannan (LAM), ESX-1 secretion-associated protein B (EspB), and Mtb8 (Rv0379) were purified by affinity chromatography, and ELISA, Western blot, and flow cytometry confirmed high antigen specificity and sensitivity for all three antibodies (Yan et al., 2025). Bioinformatics analyses of 11 mycobacterial lectins revealed that these proteins and their functional partners are predominantly extracellular and belong to the PE/PPE family. Molecular docking showed that quinoxalinone derivatives bind with good affinity to the C-type lectin Rv2075c, while fucoidan derivatives bind to the filamentous hemagglutinin-like lectin Rv1917c, suggesting their potential as vaccine candidates or drug targets (Sundar et al., 2021). Moreover, the mycobacterial virulence lipid phthiocerol dimycocerosate (PDIM) was found to induce upregulation of host macrophage Galectin-3 via Toll-like receptor 2 and non-canonical TGF-β pathways. Elevated Galectin-3 impaired NF-κB turnover and nuclear translocation, thereby suppressing proinflammatory cytokine profiles and facilitating bacterial immune evasion (Wang et al., 2025). Collectively, these chemical and immunomodulatory strategies expand the toolbox for targeting Mtb beyond direct enzyme inhibition. Novel compounds with uncharacterized mechanisms Several newly identified anti-tuberculosis agents exhibit promising activity, though their precise mechanisms remain incompletely defined. A series of pyrimidine-1,3,4-oxadiazole hybrids and their precursor amides were designed via molecular hybridization and isosteric replacement. The oxadiazole derivatives bearing C8–C12 alkyl chains displayed potent antimycobacterial activity (effective from 2 µM against Mtb H37Rv), with preliminary evidence linking their action to inhibition of cell wall biosynthesis (Pflég et al., 2023). Another novel candidate, Sudapyridine (WX-081), a pyridine analog of bedaquiline, was developed to improve safety. Preclinical studies showed that WX-081 had comparable in vitro efficacy against drug-sensitive and resistant Mtb while exhibiting weaker hERG channel inhibition and no QTc prolongation in beagle dogs, indicating a substantially reduced cardiotoxicity risk (Yao et al., 2022). Although WX-081 is known to target ATP synthase, its full mechanism of action and the basis for its improved cardiac profile are still under investigation, placing it among compounds with not-fully-elucidated mechanisms. These findings highlight the value of exploring novel chemical entities with distinct or yet-to-be-clarified modes of action. Drug delivery systems for enhanced cell wall penetration The complex and highly hydrophobic cell wall of Mycobacterium tuberculosis poses a major barrier to conventional anti-tubercular drugs, limiting their intracellular accumulation and contributing to poor treatment outcomes and drug resistance. Nanocarrier-based drug delivery systems offer a versatile platform to overcome this barrier by improving drug solubility, protecting the payload from premature degradation, enabling targeted delivery to infected macrophages, and providing sustained or triggered release. Moreover, certain nanomaterials possess intrinsic antimicrobial or immunomodulatory activities that synergize with encapsulated drugs. Nanocarriers for enhanced cell wall penetration Various nanocarriers have been designed to improve the physicochemical properties and cellular uptake of anti-tubercular drugs. Solid lipid nanoparticles co-loaded with rifampicin, isoniazid and pyrazinamide (SLN8) achieved entrapment efficiencies above 81%, sustained release, and two-fold higher activity against Mycobacterium marinum in macrophages compared to free drugs (Khatak et al., 2020). Isoniazid-loaded solid lipid nanoparticles for ocular delivery extended release to 48 h, enhanced corneal permeability 1.6-fold, and improved ocular bioavailability 4.2-fold (Singh et al., 2019). Ethambutol-loaded solid lipid nanoparticles were converted into dry powder inhalers with suitable aerodynamic properties and good biocompatibility (Nemati et al., 2019). Niosomes encapsulating ethambutol hydrochloride exhibited biphasic controlled release and improved lung targeting (El-Ridy et al., 2015). A novel isatin-isonicotinohydrazide hybrid (WF-208) incorporated into niosomes showed a 4-fold increase in anti-mycobacterial activity against H37Rv compared to the free compound, with enhanced stability under simulated gastric conditions (Eldehna et al., 2022). Dihydroartemisinin-loaded chitosan nanoparticles disrupted the cell wall of rifampicin-resistant Mtb as confirmed by electron microscopy and metabolomics (Gu et al., 2021). Rifampicin-loaded PLGA nanoparticles assembled into porous nanoparticle-aggregate particles for dry powder inhalation. After intratracheal administration, rifampicin remained detectable in lung tissue for 8 h and achieved a bioavailability of 0.72, markedly higher than oral administration (Sung et al., 2009). A microemulsion co-encapsulating rifampicin, isoniazid and pyrazinamide resolved the stability issue of rifampicin in the presence of isoniazid and provided differential release profiles (Kaur et al., 2015). Essential oil-based nanoemulsions (clove oil, cinnamon oil, eugenol) loaded with four first-line drugs exhibited sustained release for over 10 h and minimum inhibitory concentrations below 0.0009 mg/mL, outperforming free drugs (Menon et al., 2023). PLGA-PEG nanoparticles functionalized with a transferrin receptor-binding peptide delivered clofazimine across the blood-brain barrier for tuberculous meningitis, reducing cytotoxicity and enhancing transcellular permeability in brain endothelial cells (de Castro et al., 2021). Ethambutol loaded on graphene oxide-iron oxide nanocomposites provided sustained release for 50 h and superparamagnetic properties for magnetic targeting (Saifullah et al., 2017). As shown in Figure 3 (Jiang et al., 2025), different nanocarriers improve drug penetration, enable macrophage targeting, prolong half-life, achieve synergistic killing, and reduce systemic toxicity. Novel drug delivery systems for enhanced cell wall penetration. The left panel shows the impermeable mycobacterial cell wall with a red cross mark indicating poor drug penetration. The center panel displays six representative nanocarriers: niosomes, solid lipid nanoparticles, PLGA/PEG nanoparticles, essential oil-based nanoemulsions, chitosan nanoparticles, and graphene oxide-iron oxide nanocomposites. The right panel lists five therapeutic benefits: enhanced cell wall penetration, macrophage targeting, sustained/controlled release, synergistic bactericidal effect, and reduced systemic toxicity. Orange circles represent drug molecules. Targeting and administration routes Active targeting and optimized administration routes have been employed to concentrate drugs at infection sites. Mannosylation of nanostructured lipid carriers enhanced rifampicin uptake by macrophages derived from bone marrow and improved intracellular killing (Vieira et al., 2017). Stearylamine modified solid lipid nanoparticles functionalized with mannose achieved active alveolar macrophage targeting and reduced isoniazid cytotoxicity (Costa et al., 2018). A tuftsin derived peptide conjugated to rifampicin-loaded nanoparticles selectively recognized receptors on infected macrophages, doubling the anti-mycobacterial efficacy of free rifampicin (Carneiro et al., 2019). For osteoarticular tuberculosis, mannose conjugated chitosan nanoparticles loaded with rifampicin were incorporated into an injectable in situ gelling system, providing zero order release for over 40 h in simulated synovial fluid and enabling active macrophage targeting (Prabhu et al., 2021). PLGA nanocarriers co-encapsulating Q203, bedaquiline and superparamagnetic iron oxide nanoparticles achieved nearly 100% deposition in the pulmonary acinus under an external magnetic field and exhibited synergistic bactericidal activity against BCG (Poh et al., 2019). A codrug of ethionamide and its booster BDM43266 self-assembled into 200 nm nanoparticles. Intranasal delivery reduced the bacterial load 6-fold in a mouse model (Pastor et al., 2019). Ocular delivery of isoniazid using solid lipid nanoparticles allowed effective treatment of ocular tuberculosis (Singh et al., 2019). Pulmonary administration of cross-linked poly-β-cyclodextrin nanoparticles reduced lung bacterial burden via host-directed mechanisms (Machelart et al., 2019). Intrinsic antibacterial activity, synergistic effects and challenges Certain nanocarriers exhibit intrinsic antimicrobial activity and potentiate conventional anti-tubercular agents through synergistic mechanisms. Silver, zinc oxide and their composite nanoparticles inhibited the growth of MDR and XDR Mtb at concentrations as low as 1 μg/mL, although they were only bacteriostatic and showed cytotoxicity at high doses (Heidary et al., 2019). Green-synthesized gold-silver bimetallic nanoparticles using plant extracts exhibited potent anti-mycobacterial activity against both active and dormant bacilli (MIC <2.56 μg/mL) with high selectivity indices (94–108) and low cytotoxicity, offering a multi-target approach less prone to resistance (Singh et al., 2016). Dihydroartemisinin-loaded chitosan nanoparticles not only disrupted the cell wall but also synergized with rifampicin to overcome resistance, with an effective rate of 66.0% against clinical drug-resistant strains (Gu et al., 2021). Essential oil-based nanoemulsions possessed intrinsic antimicrobial activity and efficiently solubilized hydrophobic drugs, achieving MIC values below 0.0009 mg/mL through synergistic effects (Menon et al., 2023). Cross-linked poly-β-cyclodextrin nanoparticles exhibited intrinsic anti-mycobacterial activity by depleting plasma membrane cholesterol, disrupting lipid rafts, and inducing early apoptosis in infected macrophages, without genotoxicity (Machelart et al., 2019). Nevertheless, several challenges persist. High concentrations of silver nanoparticles exhibited significant cytotoxicity on THP-1 cells (Heidary et al., 2019), and further in vivo validation of safety and efficacy is required for certain nanoformulations. Future research directions should prioritize the improvement of biocompatibility, the exploration of green synthesis routes, and the integration of active targeting with synergistic drug combinations to enhance therapeutic efficacy against drug-resistant tuberculosis. Conclusions and futuristic vision The mycobacterial cell wall, with its unique and indispensable architecture, remains a cornerstone of anti-tuberculosis drug discovery. Over the past decades, systematic elucidation of the biosynthetic pathways of arabinogalactan, peptidoglycan, and mycolic acids has not only validated classical targets such as DprE1, InhA, and MmpL3 but also uncovered a wealth of new vulnerabilities, including DprE2, GlfT1, UGM, AftB, KasA, Pks13, FadD32, and the MurT-GatD complex. The discovery and optimization of inhibitors against these enzymes have produced a diverse array of chemical scaffolds with potent activity against drug-susceptible and multidrug-resistant Mycobacterium tuberculosis, several of which are advancing through clinical development. Beyond direct enzymatic inhibition, a multidimensional understanding of cell wall biology has given rise to complementary strategies, including disrupting cell wall integrity through alternative mechanisms, interfering with energy metabolism and regulatory networks, blocking the secretion and transport of essential building blocks, and harnessing host-directed therapies together with AMPs. Nanotechnology-based drug delivery systems have further empowered these efforts by overcoming the formidable permeability barrier of the mycobacterial cell wall, enabling targeted and sustained release of both existing and novel agents. Nevertheless, key challenges persist. Resistance to new inhibitors, frequently driven by mutations in target-encoding genes, underscores the urgent need for combination regimens that simultaneously attack multiple essential pathways. Tuberculosis pathology is complex, featuring heterogeneous granulomatous lesions with variable drug penetration. Consequently, it is necessary to gain a deeper understanding of pharmacokinetics and pharmacodynamics at the infection site. Successful translation of promising preclinical candidates will require rigorous evaluation in animal models that faithfully recapitulate human disease, as well as careful optimization of dosing schedules to achieve sustained drug exposure within the lesions where bacilli reside. Detailed inhibitor information and chemical structures are available in Supplementary Table S1. Looking forward, the future of cell wall-targeting anti-tuberculosis drug development will depend on the integration of several strategic directions. Continued discovery and validation of novel targets, particularly those involved in pathways specific to mycobacterium and absent in humans, will expand the therapeutic arsenal. The identification and optimization of inhibitors with improved potency, selectivity, and drug-like properties will be accelerated by the application of structure-based drug design, artificial intelligence, and machine learning. Rational design of combination therapies that target multiple essential processes holds the promise of more rapid bacterial clearance, prevention of resistance, and shortened treatment duration. Advanced drug delivery systems will be critical to overcoming the permeability barrier and achieving effective drug concentrations within granulomas. Finally, the integration of systems biology approaches will provide a holistic view of bacterial adaptation and resistance mechanisms. These approaches encompass transcriptomics, proteomics, and metabolomics, guiding the development of next-generation therapies capable of outmaneuvering pathogen evolution. Thus, exploiting the full spectrum of cell wall vulnerabilities and integrating innovative drug design and delivery technologies should enable the development of ultrashort, highly effective, and resistance-proof tuberculosis regimens. Realizing these opportunities as tangible benefits for patients worldwide will require sustained dedication to basic research, translational science, and clinical innovation.